Skip to main content
. Author manuscript; available in PMC: 2018 Jun 15.
Published in final edited form as: Adv Drug Deliv Rev. 2017 Jun 15;114:285–300. doi: 10.1016/j.addr.2017.06.010

Figure 3. Effect of epigenetic inhibitors on immune cells and modes of epigenetic drug delivery.

Figure 3

(A) Epigenetic drugs offer multi-modal approach to targeting malignant B cells. While EZH2 inhibitors exclusively affect malignant B cells, HDAC inhibitors (HDACi) also enhance chemokines, interleukins, and interferons while inhibiting the proliferation of regulatory T cells. Similarly, DNMT inhibitors (DNMTi) enhances nKGG2D receptors on natural killer cells while enhancing MHC class I, PDL-1, tumor antigens, and cytokines from malignant B cells. (B) Targeted drug delivery to cancer cells function through two pathways: cytotoxicity of cancer cells and epigenetic reprogramming through various epigenetic regulating drugs. Nanoparticle drug delivery platforms improve outcomes through enhanced drug stability and sustained drug release over soluble drug delivery paradigms.